77 related articles for article (PubMed ID: 38655365)
21. Clinical big-data-based design of GLUT2-targeted carbon nanodots for accurate diagnosis of hepatocellular carcinoma.
Heo HJ; Park Y; Lee JH; Kim Y; Kim EK; Kim GH; Yu Y; Park SY; Seo HB; Pak K; Goh TS; Park S; Oh SO; Kwon W; Kim YH
Nanoscale; 2022 Nov; 14(45):17053-17064. PubMed ID: 36367284
[TBL] [Abstract][Full Text] [Related]
22. Metabolic Recruitment in Brain Tissue.
Barros LF; Ruminot I; Sotelo-Hitschfeld T; Lerchundi R; Fernández-Moncada I
Annu Rev Physiol; 2023 Feb; 85():115-135. PubMed ID: 36270291
[TBL] [Abstract][Full Text] [Related]
23. MicroRNAs-mediated regulation of glucose transporter (GLUT) expression in glioblastoma.
Beylerli O; Sufianova G; Shumadalova A; Zhang D; Gareev I
Noncoding RNA Res; 2022 Dec; 7(4):205-211. PubMed ID: 36157351
[TBL] [Abstract][Full Text] [Related]
24.
Wang Y; Wen H; Sun D
Ann Transl Med; 2022 May; 10(9):519. PubMed ID: 35928739
[TBL] [Abstract][Full Text] [Related]
25. GLUT1 Regulates the Tumor Immune Microenvironment and Promotes Tumor Metastasis in Pancreatic Adenocarcinoma via ncRNA-mediated Network.
Li F; He C; Yao H; Liang W; Ye X; Ruan J; Lin L; Zou J; Zhou S; Huang Y; Li Y; Chen S; Huang K; Lian G; Chen S
J Cancer; 2022; 13(8):2540-2558. PubMed ID: 35711842
[TBL] [Abstract][Full Text] [Related]
26. Predicting Differences in Treatment Response and Survival Time of Lung Adenocarcinoma Patients Based on a Prognostic Risk Model of Glycolysis-Related Genes.
Zhao R; Ding D; Ding Y; Han R; Wang X; Zhu C
Front Genet; 2022; 13():828543. PubMed ID: 35692818
[No Abstract] [Full Text] [Related]
27. Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration.
Peng Q; Hao LY; Guo YL; Zhang ZQ; Ji JM; Xue Y; Liu YW; Lu JL; Li CG; Shi XL
World J Clin Cases; 2022 May; 10(13):3989-4019. PubMed ID: 35665115
[TBL] [Abstract][Full Text] [Related]
28. PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference.
Shearer AM; Wang Y; Fletcher EK; Rana R; Michael ES; Nguyen N; Abdelmalek MF; Covic L; Kuliopulos A
Hepatology; 2022 Dec; 76(6):1778-1793. PubMed ID: 35603482
[TBL] [Abstract][Full Text] [Related]
29. Molecular basis for inhibiting human glucose transporters by exofacial inhibitors.
Wang N; Zhang S; Yuan Y; Xu H; Defossa E; Matter H; Besenius M; Derdau V; Dreyer M; Halland N; He KH; Petry S; Podeschwa M; Tennagels N; Jiang X; Yan N
Nat Commun; 2022 May; 13(1):2632. PubMed ID: 35552392
[TBL] [Abstract][Full Text] [Related]
30. Cancer proteogenomics: current impact and future prospects.
Mani DR; Krug K; Zhang B; Satpathy S; Clauser KR; Ding L; Ellis M; Gillette MA; Carr SA
Nat Rev Cancer; 2022 May; 22(5):298-313. PubMed ID: 35236940
[TBL] [Abstract][Full Text] [Related]
31. Genomic Instability of Mutation-Derived Gene Prognostic Signatures for Hepatocellular Carcinoma.
Song ZB; Yu Y; Zhang GP; Li SQ
Front Cell Dev Biol; 2021; 9():728574. PubMed ID: 34676211
[TBL] [Abstract][Full Text] [Related]
32. GLUT4-overexpressing engineered muscle constructs as a therapeutic platform to normalize glycemia in diabetic mice.
Beckerman M; Harel C; Michael I; Klip A; Bilan PJ; Gallagher EJ; LeRoith D; Lewis EC; Karnieli E; Levenberg S
Sci Adv; 2021 Oct; 7(42):eabg3947. PubMed ID: 34644106
[TBL] [Abstract][Full Text] [Related]
33. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming.
Morrissey SM; Zhang F; Ding C; Montoya-Durango DE; Hu X; Yang C; Wang Z; Yuan F; Fox M; Zhang HG; Guo H; Tieri D; Kong M; Watson CT; Mitchell RA; Zhang X; McMasters KM; Huang J; Yan J
Cell Metab; 2021 Oct; 33(10):2040-2058.e10. PubMed ID: 34559989
[TBL] [Abstract][Full Text] [Related]
34. Glucose Metabolism and Glucose Transporters in Breast Cancer.
Shin E; Koo JS
Front Cell Dev Biol; 2021; 9():728759. PubMed ID: 34552932
[TBL] [Abstract][Full Text] [Related]
35. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
36. Glucose Transporters as a Target for Anticancer Therapy.
Pliszka M; Szablewski L
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439338
[TBL] [Abstract][Full Text] [Related]
37. Screening and Validation of the Hypoxia-Related Signature of Evaluating Tumor Immune Microenvironment and Predicting Prognosis in Gastric Cancer.
Pei JP; Zhang CD; Yusupu M; Zhang C; Dai DQ
Front Immunol; 2021; 12():705511. PubMed ID: 34249015
[TBL] [Abstract][Full Text] [Related]
38. Decreased GLUT2 and glucose uptake contribute to insulin secretion defects in MODY3/HNF1A hiPSC-derived mutant β cells.
Low BSJ; Lim CS; Ding SSL; Tan YS; Ng NHJ; Krishnan VG; Ang SF; Neo CWY; Verma CS; Hoon S; Lim SC; Tai ES; Teo AKK
Nat Commun; 2021 May; 12(1):3133. PubMed ID: 34035238
[TBL] [Abstract][Full Text] [Related]
39. Cancer Cells' Metabolism Dynamics in Renal Cell Carcinoma Patients' Outcome: Influence of GLUT-1-Related hsa-miR-144 and hsa-miR-186.
Morais M; Dias F; Nogueira I; Leão A; Gonçalves N; Araújo L; Granja S; Baltazar F; Teixeira AL; Medeiros R
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33917405
[TBL] [Abstract][Full Text] [Related]
40. Clinical cancer genomic profiling.
Chakravarty D; Solit DB
Nat Rev Genet; 2021 Aug; 22(8):483-501. PubMed ID: 33762738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
